Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer

BURLINGTON, Mass., Dec. 11, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Scott Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley previously served as the company’s Vice President of Medical Affairs, and in his new role, he assumes responsibility for all medical matters at Flexion, including Medical Affairs, Clinical Research and Clinical Operations.

“Scott has demonstrated a singular combination of rigor and creativity with respect to clinical trial design, clinical data analysis and the consideration of pipeline candidates, and he melds those skills with an innate ability to communicate ideas and data with passion and clarity,” said Michael Clayman, M.D., President and Chief Executive Officer of Flexion. “Scott’s promotion reflects his impressive capabilities and accomplishments, and we look forward to his continued success in his expanded role at this critical juncture in the company’s evolution.”

Prior to joining Flexion in May of 2016, Dr. Kelley served as Vice President, Global Medical Affairs, at Sanofi, where he oversaw global data generation, data dissemination and key opinion leader engagement for the Biosurgery portfolio including Synvisc^®. Previously, he led medical affairs functions at Covidien Respiratory & Monitoring Solutions and Aspect Medical Systems. He obtained his bachelor’s and master’s degrees from Stanford University and earned his medical degree at the University of California, San Francisco (UCSF). He completed his residency and fellowship in anesthesiology at UCSF and obtained board certifications in anesthesiology and pain management.

Dr. Kelley succeeds Yamo Deniz, M.D., who has left the company to pursue other opportunities.

About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of the Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.

Forward-Looking Statements
Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements relating to the future expected benefits of Flexion’s appointment of Dr. Kelley to Chief Medical Officer, are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, whether we are able to retain key employees including Dr. Kelley; our ability to meet our goals; and other risks and uncertainties described in our filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 filed with the SEC on November 6, 2017. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the statements. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Contacts:

Scott Young                                                                                                   
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]